Lenvatinib in Relapsed/Metastatic Adenoid Cystic Carcinoma: Real‐World Data From 17 Italian Centers
Head & Neck · 2025-07 · 47 (7) · 2040-2047
DOI: 10.1002/hed.28124 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Head & Neck, online erschienen am 03.03.2025. Verfasst von Francesca Caspani und 19 weiteren Autor:innen. Beteiligte Einrichtung: Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy. Hauptthemen laut MEDLINE: Quinolines, Carcinoma, Adenoid Cystic, Phenylurea Compounds, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Background
Lenvatinib, a multi‐target tyrosine kinase inhibitor (MTKI), has demonstrated activity in recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC) in phase II studies.
Methods
This multicenter, retrospective study included patients with R/M ACC treated with lenvatinib. The primary endpoint was the overall response rate (ORR).
Results
Fifty‐one patients were included across 17 Italian sites. Forty‐six patients (90%) were evaluated for response: the ORR was 21.7%, with 10 patients achieving a partial response; 24 patients had a stable disease resulting in a disease control rate of 73.9%. At least one treatment‐related adverse event (TRAE) was recorded in all patients. The most frequent TRAEs of grade > 3 were hypertension (25.5%), stomatitis (17.6%), and fatigue (15.7%); one grade 5 TRAE (bleeding) was reported. Median OS was 16.1 months (95% CI 12.2‐NR) with six‐month PFS at 75.7%.
Conclusion
Lenvatinib confirmed its activity in the real‐world population. A higher than expected rate of grade > 3 stomatitis was reported.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
- Fondazione CNAO - Centro Nazionale di Adroterapia Oncologica, Radiotherapy, Pavia, Italy.
- Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy.
- CRO IRCCS, Head and Neck Medical Oncology, Aviano, Italy.
- San Raffaele Hospital, Medical Oncology, Milan, Italy.
ORCID-Profile: Francesca Caspani, Stefano Cavalieri, Cristiana Bergamini, Salvatore Alfieri, Laura D Locati
Zitieren
APA
Caspani, F., Cavalieri, S., Orlandi, E., Bergamini, C., Resteghini, C., Colombo, E., Ottini, A., Nuzzolese, I., Alfieri, S., Mirabile, A., Cassano, A., Bossi, P., Ibrahim, T., Cau, M. C., Ghiani, M., Bertolini, F., Ingargiola, R., Fontana, G., Licitra, L., & Locati, L. D. (2025). Lenvatinib in Relapsed/Metastatic Adenoid Cystic Carcinoma: Real‐World Data From 17 Italian Centers. Head & Neck, 47(7), 2040-2047. https://doi.org/10.1002/hed.28124
Vancouver
Caspani F, Cavalieri S, Orlandi E, Bergamini C, Resteghini C, Colombo E, et al. Lenvatinib in Relapsed/Metastatic Adenoid Cystic Carcinoma: Real‐World Data From 17 Italian Centers. Head & Neck. 2025;47(7):2040-2047. doi:10.1002/hed.28124
BibTeX
@article{Caspani2025,
author = {Caspani, Francesca and Cavalieri, Stefano and Orlandi, Ester and Bergamini, Cristiana and Resteghini, Carlo and Colombo, Elena and Ottini, Arianna and Nuzzolese, Imperia and Alfieri, Salvatore and Mirabile, Aurora and Cassano, Alessandra and Bossi, Paolo and Ibrahim, Toni and Cau, Maria Chiara and Ghiani, Massimo and Bertolini, Federica and Ingargiola, Rossana and Fontana, Giulia and Licitra, Lisa and Locati, Laura D},
title = {Lenvatinib in Relapsed/Metastatic Adenoid Cystic Carcinoma: Real‐World Data From 17 Italian Centers},
journal = {Head & Neck},
year = {2025},
volume = {47},
number = {7},
pages = {2040--2047},
doi = {10.1002/hed.28124}
}
EUVIMED